GM26 Company Profile

Facing challenging business enviroment, with rather steep -19.762 %, Sales decrease, the Eiger Biopharmaceuticals Inc during the fiscal fourth quarter of 2022

For the fiscal period ending December 31 2022 Eiger Biopharmaceuticals Inc managed to trim its losses on fading revenue, where loss per share were at $-0.46 in proportion to $-0.64 and revenue decreased by -19.762 % to $2.70 millions in contrast to $3.36 millions in the similar reporting period a year prior.

For the financial interval closing December 31 2022 SESG had turn a round to surplus by presenting earnings per share of $1.89 per share compare to $-0.64 a year prior and earnings per share turned positive from $-2.11 per share from the preceding quarter.

Sales remained unaffected to $0.00 millions from $3.36 millions in the comparable quarter a year prior and sequentially Sales Tumbled from $0.00 millions.

Compelling time frame by the company in the October to December 31 2022 three months

For the fourth quarter of 2022 company reached 0 of $0.00 per share compare to $0.00 a year prior and from $0.00 per share from the previous reporting period.

Sales grew strongly by 54.111 % to $75.28 millions from $48.85 millions in the corresponding reporting period a year prior and sequentially Sales deteriorated by -13.874 % from $87.41 millions.

Ambev S A has Bottom and Top-line growth for the financial time-frame ending December 31 2022. Sales were at $15.14 billions increased by 9.409 % year on year and deteriorated by 0 % quarter on quarter, while net profit per share grew by 14.17 % to $0.17, sequentially by 0 %.

Shortfall higher than a year ago at the Wisa Technologies Inc in the October to December 31 2022 time-frame

the Semiconductors company disclosed disastrous most recent fiscal period, where Sales faded by -54.2 % to $0.92 millions and net deficit per share has extended to $-0.23, from the similar financial reporting period a year ago.